FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3011636404> ?p ?o ?g. }

• W3011636404 endingPage "713" @default.
• W3011636404 startingPage "705" @default.
• W3011636404 abstract "The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive and prognostic biomarkers for metastatic castration-resistant prostate cancer (mCRPC). Serial plasma specimens were prospectively collected from 88 chemotherapy-naive mCRPC patients before and after 12 weeks of AA/P treatment. Sequencing-based CNA analyses were performed on 174 specimens. We evaluated CNA-associated 12-week responses for primary resistance, time to treatment change (TTTC) for secondary resistance, and overall survival for prognosis (P < 0.05). Associations with primary resistance were analyzed using the Fisher exact test. Kaplan–Meier survival curves and Cox regression analyses were used to determine the associations of CNAs with acquired resistance and overall survival. ctDNA reduced by 3.89% in responders and increased by 0.94% in nonresponders (P = 0.0043). Thirty-one prostate cancer-related genes from whole genome CNAs were tested. AR and AR enhancer amplification were associated with primary resistance (P = 0.0039) and shorter TTTC (P = 0.0003). ZFHX3 deletion and PIK3CA amplification were associated with primary resistance (P = 0.026 and P = 0.017, respectively), shorter TTTC (P = 0.0008 and P = 0.0016, respectively), and poor survival (P = 0.0025 and P = 0.0022, respectively). CNA-based risk scores combining selected significant associations (AR, NKX3.1, and PIK3CA) at the univariate level with TTTC were predictive of secondary resistance (P = 0.0002). and established prognoses for survival based on CNAs in ZFHX3, RB1, PIK3CA, and OPHN1 (P = 0.002). Multigene risk scores were more predictive than individual genes or clinical risk factors (P < 0.05). Plasma ctDNA CNAs and risk scores can predict mCRPC-state treatment and survival outcomes." @default.
• W3011636404 created "2020-03-23" @default.
• W3011636404 creator A5006833753 @default.
• W3011636404 creator A5018184772 @default.
• W3011636404 creator A5021900842 @default.
• W3011636404 creator A5055761984 @default.
• W3011636404 creator A5057146540 @default.
• W3011636404 creator A5057501732 @default.
• W3011636404 creator A5069578729 @default.
• W3011636404 creator A5079544772 @default.
• W3011636404 creator A5086664647 @default.
• W3011636404 date "2020-03-18" @default.
• W3011636404 modified "2023-10-14" @default.
• W3011636404 title "Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer" @default.
• W3011636404 cites W1578291413 @default.
• W3011636404 cites W1805253056 @default.
• W3011636404 cites W2011957420 @default.
• W3011636404 cites W2045921760 @default.
• W3011636404 cites W2051025382 @default.
• W3011636404 cites W2099367648 @default.
• W3011636404 cites W2121098984 @default.
• W3011636404 cites W2137467802 @default.
• W3011636404 cites W2160463964 @default.
• W3011636404 cites W2161112598 @default.
• W3011636404 cites W2167331614 @default.
• W3011636404 cites W2181283187 @default.
• W3011636404 cites W2235523093 @default.
• W3011636404 cites W2292362441 @default.
• W3011636404 cites W2338191132 @default.
• W3011636404 cites W2398715868 @default.
• W3011636404 cites W2403998898 @default.
• W3011636404 cites W2472811390 @default.
• W3011636404 cites W2507921127 @default.
• W3011636404 cites W2612083582 @default.
• W3011636404 cites W2614124974 @default.
• W3011636404 cites W2725414935 @default.
• W3011636404 cites W2754374178 @default.
• W3011636404 cites W2759902374 @default.
• W3011636404 cites W2765435739 @default.
• W3011636404 cites W2766051395 @default.
• W3011636404 cites W2767666623 @default.
• W3011636404 cites W2789730857 @default.
• W3011636404 cites W2790119669 @default.
• W3011636404 cites W2805161901 @default.
• W3011636404 cites W2807985734 @default.
• W3011636404 cites W2810684981 @default.
• W3011636404 cites W2884001931 @default.
• W3011636404 cites W2892240038 @default.
• W3011636404 cites W2893855020 @default.
• W3011636404 cites W2899109449 @default.
• W3011636404 cites W2911655697 @default.
• W3011636404 cites W2916300526 @default.
• W3011636404 cites W2926930280 @default.
• W3011636404 cites W2951423138 @default.
• W3011636404 cites W3147725646 @default.
• W3011636404 cites W4255872155 @default.
• W3011636404 doi "https://doi.org/10.1038/s41391-020-0224-4" @default.
• W3011636404 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7501185" @default.
• W3011636404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32203070" @default.
• W3011636404 hasPublicationYear "2020" @default.
• W3011636404 type Work @default.
• W3011636404 sameAs 3011636404 @default.
• W3011636404 citedByCount "14" @default.
• W3011636404 countsByYear W30116364042020 @default.
• W3011636404 countsByYear W30116364042021 @default.
• W3011636404 countsByYear W30116364042022 @default.
• W3011636404 countsByYear W30116364042023 @default.
• W3011636404 crossrefType "journal-article" @default.
• W3011636404 hasAuthorship W3011636404A5006833753 @default.
• W3011636404 hasAuthorship W3011636404A5018184772 @default.
• W3011636404 hasAuthorship W3011636404A5021900842 @default.
• W3011636404 hasAuthorship W3011636404A5055761984 @default.
• W3011636404 hasAuthorship W3011636404A5057146540 @default.
• W3011636404 hasAuthorship W3011636404A5057501732 @default.
• W3011636404 hasAuthorship W3011636404A5069578729 @default.
• W3011636404 hasAuthorship W3011636404A5079544772 @default.
• W3011636404 hasAuthorship W3011636404A5086664647 @default.
• W3011636404 hasBestOaLocation W30116364042 @default.
• W3011636404 hasConcept C121608353 @default.
• W3011636404 hasConcept C126322002 @default.
• W3011636404 hasConcept C143998085 @default.
• W3011636404 hasConcept C2775832370 @default.
• W3011636404 hasConcept C2776694085 @default.
• W3011636404 hasConcept C2777899217 @default.
• W3011636404 hasConcept C2778720950 @default.
• W3011636404 hasConcept C2780192828 @default.
• W3011636404 hasConcept C2780739268 @default.
• W3011636404 hasConcept C50382708 @default.
• W3011636404 hasConcept C71924100 @default.
• W3011636404 hasConceptScore W3011636404C121608353 @default.
• W3011636404 hasConceptScore W3011636404C126322002 @default.
• W3011636404 hasConceptScore W3011636404C143998085 @default.
• W3011636404 hasConceptScore W3011636404C2775832370 @default.
• W3011636404 hasConceptScore W3011636404C2776694085 @default.
• W3011636404 hasConceptScore W3011636404C2777899217 @default.
• W3011636404 hasConceptScore W3011636404C2778720950 @default.
• W3011636404 hasConceptScore W3011636404C2780192828 @default.
• W3011636404 hasConceptScore W3011636404C2780739268 @default.

• next